This trial is studying the effects of ranibizumab given through the Port Delivery System in people with diabetic retinopathy without center-involved diabetic macular edema.
1 Primary · 35 Secondary · Reporting Duration: Baseline up to Week 112
Experimental Treatment
174 Total Participants · 1 Treatment Group
Primary Treatment: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab · No Placebo Group · Phase 3
Age 18+ · All Participants · 6 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Texas | 33.3% |
New York | 33.3% |
Maryland | 16.7% |
Other | 16.7% |
18 - 65 | 80.0% |
65+ | 20.0% |
Retina Group of Washington | 25.0% |
Midwest Vision Research Foundation | 25.0% |
Retina Consultants of Texas | 25.0% |
Other | 25.0% |
Met criteria | 80.0% |
Did not meet criteria | 20.0% |